Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4RD0C
|
|||
| Drug Name |
Bamosiran
|
|||
| Synonyms |
SYL040012
Click to Show/Hide
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Glaucoma/ocular hypertension [ICD-11: 9C61] | Phase 2 | [1] | |
| Company |
Sylentis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ADRB2 messenger RNA (ADRB2 mRNA) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta2 adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma (SYLTAG). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Sylentis. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.